Halozyme Therapeutics Ownership | Who Owns Halozyme Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Halozyme Therapeutics Ownership Summary


Halozyme Therapeutics is owned by 55.73% institutional investors, 1.42% insiders, and 42.86% retail investors. Blackrock is the largest institutional shareholder, holding 13.88% of HALO shares. iShares Core S&P Mid-Cap ETF is the top mutual fund, with 3.36% of its assets in Halozyme Therapeutics shares.

HALO Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockHalozyme Therapeutics55.73%1.42%42.86%
SectorHealthcare Stocks 57.39%9.93%32.68%
IndustryBiotech Stocks 68.48%9.65%21.87%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock17.62M13.88%$922.58M
Blackrock funding, inc. /de17.57M13.85%$839.84M
Vanguard group13.28M10.47%$635.00M
State street5.81M4.58%$304.43M
Snyder capital management l p4.17M3.29%$199.29M
Alliancebernstein3.07M2.42%$146.70M
Geode capital management3.06M2.42%$146.53M
Macquarie group2.91M2.29%$138.91M
Jpmorgan chase2.39M1.88%$114.15M
Invesco2.37M1.87%$113.52M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Snyder capital management l p4.17M4.17%$199.29M
Steamboat capital partners249.75K3.69%$11.94M
2xideas498.96K3.26%$26.13M
Koa wealth management82.41K3.22%$3.94M
Castellan group116.47K2.41%$5.57M
Future fund17.60K2.40%$841.26K
Bernzott capital advisors93.98K2.22%$4.49M
Harvey capital management185.44K2.09%$8.87M
South street advisors229.76K1.68%$10.99M
Shaker investments llc/oh75.33K1.51%$3.60M

Top Buyers

HolderShares% AssetsChange
Norges bank1.26M0.01%1.26M
Capital world investors748.23K0.01%748.23K
Arrowstreet capital, limited partnership992.89K0.04%581.48K
D. e. shaw831.41K0.03%524.80K
Invesco2.37M0.02%462.76K

Top Sellers

HolderShares% AssetsChange
Artisan partners limited partnership1.37M0.10%-1.76M
Handelsbanken fonder ab516.47K0.09%-1.45M
Frontier capital management---1.27M
Cibc private wealth group3.05K0.00%-963.45K
State street5.81M0.01%-673.10K

New Positions

HolderShares% AssetsChangeValue
Norges bank1.26M0.01%1.26M$60.05M
Capital world investors748.23K0.01%748.23K$35.77M
Raymond james financial456.77K0.01%456.77K$21.84M
Abrdn128.67K0.01%128.67K$6.15M
Clark capital management group102.92K0.04%102.92K$5.39M

Sold Out

HolderChange
Harbor investment advisory-4.00
Newbridge financial services group-10.00
Cranbrook wealth management-13.00
Fortitude family office-18.00
Jnba financial advisors-24.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2024292-43.41%70,690,093-43.61%550.57%130-52.38%114-30.91%
Sep 30, 20245109.68%124,779,1382.05%981.06%27011.57%1653.77%
Jun 30, 20244589.05%122,203,811-0.27%961.03%2378.22%15811.27%
Mar 31, 2024420-0.24%122,538,335-1.36%961.09%2192.82%142-0.70%
Dec 31, 20234215.25%124,225,8342.20%941.11%21318.33%143-2.05%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
iShares Core S&P Mid-Cap ETF4.16M3.36%7.29K
Vanguard US Total Market Shares ETF4.03M3.27%3.36K
Vanguard Total Stock Mkt Idx Inv4.01M3.25%2.32K
iShares Russell 2000 ETF3.28M2.66%-28.43K
Vanguard Small Cap Index3.25M2.64%2.65K
Aviva Investors GlConvtAbsRet I USD Acc2.74M2.16%2.74M
Vanguard Institutional Extnd Mkt Idx Tr1.93M1.57%4.37K
Vanguard Small Cap Growth Index Inv1.82M1.48%-10.66K
Macquarie Small Cap Core I1.74M1.41%-
Vanguard Explorer Inv1.76M1.39%-219.70K

Recent Insider Transactions


DateNameRoleActivityValue
Apr 01, 2025Henderson Jeffrey William-Sell$32.22K
Mar 03, 2025Henderson Jeffrey William-Sell$189.47K
Mar 03, 2025Henderson Jeffrey William-Sell$103.99K
Feb 25, 2025LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICERSell$41.07K
Feb 26, 2025LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICERSell$546.06K

Insider Transactions Trends


DateBuySell
2025 Q2-1
2025 Q1-11
2024 Q4-8
2024 Q3-25
2024 Q2-10

HALO Ownership FAQ


Who Owns Halozyme Therapeutics?

Halozyme Therapeutics shareholders are primarily institutional investors at 55.73%, followed by 1.42% insiders and 42.85% retail investors. The average institutional ownership in Halozyme Therapeutics's industry, Biotech Stocks , is 68.48%, which Halozyme Therapeutics falls below.

Who owns the most shares of Halozyme Therapeutics?

Halozyme Therapeutics’s largest shareholders are Blackrock (17.62M shares, 13.88%), Blackrock funding, inc. /de (17.57M shares, 13.85%), and Vanguard group (13.28M shares, 10.47%). Together, they hold 38.20% of Halozyme Therapeutics’s total shares outstanding.

Does Blackrock own Halozyme Therapeutics?

Yes, BlackRock owns 13.88% of Halozyme Therapeutics, totaling 17.62M shares as of Jun 2024. This represents 0.02% of BlackRock's total assets, with a market value of 922.58M$. In the last quarter, BlackRock decreased its holdings by -622K shares, a -3.41% change.

Who is Halozyme Therapeutics’s biggest shareholder by percentage of total assets invested?

Snyder capital management l p is Halozyme Therapeutics’s biggest shareholder by percentage of total assets invested, with 4.17% of its assets in 4.17M Halozyme Therapeutics shares, valued at 199.29M$.

Who is the top mutual fund holder of Halozyme Therapeutics shares?

iShares Core S&P Mid-Cap ETF is the top mutual fund holder of Halozyme Therapeutics shares, with 3.36% of its total shares outstanding invested in 4.16M Halozyme Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools